SCD5 expression correlates with prognosis and response to neoadjuvant chemotherapy in breast cancer

Neoadjuvant chemotherapy (NACT) represents a standard option for breast cancer. Unfortunately, about 55–80% of breast cancer patients do not have a favorable response to chemotherapy. Highly specific tumor biomarker that can predict the pathological response to neoadjuvant chemotherapy is lacking. S...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Weipeng, Sun, Linlin, Li, Xichuan, Wang, Jun, Zhu, Ye, Jia, Yan, Tong, Zhongsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076324/
https://www.ncbi.nlm.nih.gov/pubmed/33903614
http://dx.doi.org/10.1038/s41598-021-88258-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076324/
https://www.ncbi.nlm.nih.gov/pubmed/33903614
http://dx.doi.org/10.1038/s41598-021-88258-9

Ejemplares similares